Your browser doesn't support javascript.
Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors.
Martin, M Carmen; Jimenez, Ana; Ortega, Nuria; Parrado, Alba; Page, Isabel; Gonzalez, M Isabel; Blanco-Peris, Lydia.
  • Martin MC; Centro de Hemoterapia y Hemodonacion de Castilla y Leon, Valladolid, Castilla y León, Spain.
  • Jimenez A; Centro de Hemoterapia y Hemodonacion de Castilla y Leon, Valladolid, Castilla y León, Spain.
  • Ortega N; Centro de Hemoterapia y Hemodonacion de Castilla y Leon, Valladolid, Castilla y León, Spain.
  • Parrado A; Centro de Hemoterapia y Hemodonacion de Castilla y Leon, Valladolid, Castilla y León, Spain.
  • Page I; Centro de Hemoterapia y Hemodonacion de Castilla y Leon, Valladolid, Castilla y León, Spain.
  • Gonzalez MI; Centro de Hemoterapia y Hemodonacion de Castilla y Leon, Valladolid, Castilla y León, Spain.
  • Blanco-Peris L; Centro de Hemoterapia y Hemodonacion de Castilla y Leon, Valladolid, Castilla y León, Spain.
PLoS One ; 17(2): e0264124, 2022.
Article in English | MEDLINE | ID: covidwho-1703795
ABSTRACT

BACKGROUND:

The vast majority of COVID-19 cases both symptomatic and asymptomatic develop immunity after COVID-19 contagion. Whether lasting differences exist between infection and vaccination boosted immunity is yet to be known. The aim of this study was to determine how long total anti-SARS-CoV2 antibodies due to past infection persist in peripheral blood and whether sex, age or haematological features can influence their lasting. MATERIAL AND

METHODS:

A series of 2421 donations either of SARS-CoV-2 convalescent plasma or whole blood from 1107 repeat donors from January 2020 to March 2021 was analysed. An automated chemiluminescence immunoassay for total antibodies recognizing the nucleocapsid protein of SARS-CoV-2 in human serum and plasma was performed. Sex, age, blood group, blood cell counts and percentages and immunoglobulin concentrations were extracted from electronic recordings. Blood donation is allowed after a minimum of one-month post symptom's relapse. Donors were 69.7% males and their average age was 46. The 250 donors who had later donations after a positive one underwent further analysis. Both qualitative (positivity) and quantitative (rise or decline of optical density regarding consecutive donations) outcomes were evaluated. RESULTS AND

DISCUSSION:

In 97.6% of donors with follow-up, anti-SARS-CoV-2 protein N total antibodies remained positive at the end of a follow-up period of 12.4 weeks median time (1-46, SD = 9.65) after the first positive determination. The blood group was not related to antibody waning. Lower lymphocyte counts and higher neutrophils would help predict future waning or decay of antibodies. Most recovered donors maintain their total anti-SARS-CoV-2 N protein antibodies for at least 16 weeks (at least one month must have been awaited from infection resolution to blood donation). The 10 individuals that could be followed up longer than 40 weeks (approximately 44 weeks after symptom's relapse) were all still positive.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Prognostic study / Qualitative research Topics: Long Covid / Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0264124

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Prognostic study / Qualitative research Topics: Long Covid / Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0264124